Pathogenesis and potential antiviral therapy of complications of smallpox vaccination (Q35125810)

6 August 2017

1 reference

title

Pathogenesis and potential antiviral therapy of complications of smallpox vaccination (English)

1 reference

6 August 2017

0 references

1 reference

0 references

1 reference

https://api.crossref.org/works/10.1016/S0166-3542(03)00008-1

1 January 2024

1

Mike Bray

1 reference

6 August 2017

language of work or name

1 reference

1 April 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0166354203000081?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0166-3542(03)00008-1

https://api.elsevier.com/content/article/PII:S0166354203000081?httpAccept=text/plain

1 January 2024

1 reference

https://api.crossref.org/works/10.1016/S0166-3542(03)00008-1

1 January 2024

1 reference

6 August 2017

volume

58

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

101-114

1 reference

Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Topical use of cidofovir induced acute renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

ANTIBODY RESPONSE TO CUTANEOUS INOCULATION WITH VACCINIA VIRUS: VIREMIA AND VIRURIA IN VACCINATED CHILDREN.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Methisazone in progressive vaccinia

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

1 reference

7 January 2021

Human immunodeficiency virus infections among civilian applicants for United States military service, October 1985 to March 1986. Demographic factors associated with seropositivity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

1 reference

7 January 2021

Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Cidofovir in the treatment of poxvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Treatment of progressive vaccinia. Use of methisazone, vaccinia immune serum globulin, and surgical debridement

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Smallpox vaccination: Risk considerations for patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Herpesvirus infection in burned patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Clinical responses to undiluted and diluted smallpox vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Therapy of experimental vaccinal keratitis. Effect of idoxuridine and VIG

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

A case of human orf in an immunocompromised patient treated successfully with cidofovir cream

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

The effect of antivaccinia gamma globulin on smallpox vaccination in view of a proposed attempt to prevent postvaccinal encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Placebo-controlled trial of topical interferon in labial and genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Clinical investigation of patients with agammaglobulinemia and hypogammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Vaccinia from recombinant virus expressing HIV genes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

A recombinant vaccinia-rabies virus in the immunocompromised host: oral innocuity, progressive parenteral infection, and therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Bioterrorism as a public health threat

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Smallpox as a Biological Weapon

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Clearance of recombinant vaccinia virus expressing IL-2: role of local host immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Treatment of vaccinial keratitis with vidarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Treatment of Vaccinial keratitis with trifluorothymidine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Treatment with Methisazone of Complications following Smallpox Vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Vaccinial keratitis treated with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Treatment of viral diseases of the cornea and external eye.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Cure of vaccinia infection by 5-iodo-2′-deoxyuridine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

In vitro activity of potential anti-poxvirus agents

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Progressive vaccinia treated with ribavirin and vaccinia immune globulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Complications of smallpox vaccination, 1968.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Smallpox and smallpox vaccination policy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Vaccinia keratouveitis manifesting as a masquerade syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Atopic dermatitis: new insights and opportunities for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Topical treatment of vaccinia virus infection with an interferon inducer in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Complications of small-pox vaccination and their treatment with vaccinia immune gamma globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Immunologic responses to vaccinia vaccines administered by different parenteral routes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Methisazone therapy in pediatric vaccinia complications

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Immunomodulation as a treatment strategy for genital herpes: review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Complications of smallpox vaccination. I. National survey in the United States, 1963.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Contact vaccinia--transmission of vaccinia from smallpox vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for treatment of vaccinia virus (orthopoxvirus) infections in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Effect of 5-iodo-2'-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Endogenous antimicrobial peptides and skin infections in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

The laboratory and clinical assessment of an isothiazole thiosemicarbazone (M 2 b 7714) against pox viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

The smallpox vaccine and postvaccinal encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

1 reference

7 January 2021

Ocular vaccinia. An epidemiologic analysis of 348 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Effect of human fibroblast interferon on vaccination in volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

How contagious is vaccinia?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Experience of anti-vaccinia immunoglobulin in the United Kingdom.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Effect of 1-beta-D-ribofuranosyl1-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Smallpox and pregnancy: from eradicated disease to bioterrorist threat

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

NC/Nga mice: a mouse model for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Eczema vaccinatum treated with n-methylisatin beta-thiosemicarbazone.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Vaccinia necrosum: a forgotten disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Effect of Polyriboinosinic-Polyribocytidylic Acid and Antibody on Infection of Immunosuppressed Mice with Vaccinia Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Treatment of Fatal Disseminated Vaccinia Virus Infection in Immunosuppressed Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2803%2900008-1

7 January 2021

Animal poxviruses transmitted from cat to man: current event with lethal end

13

1 reference

https://api.crossref.org/works/10.1016/S0166-3542(03)00008-1

STUDIES ON SMALLPOX AND COMPLICATIONS OF SMALLPOX VACCINATION

1 January 2024

49

1 reference

https://api.crossref.org/works/10.1016/S0166-3542(03)00008-1

Expected adverse events in a mass smallpox vaccination campaign

1 January 2024

51

1 reference

https://api.crossref.org/works/10.1016/S0166-3542(03)00008-1

Progressive vaccinia with chronic lymphatic leukaemia: a case report

1 January 2024

64

1 reference

https://api.crossref.org/works/10.1016/S0166-3542(03)00008-1

Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model

1 January 2024

83

1 reference

https://api.crossref.org/works/10.1016/S0166-3542(03)00008-1

Vaccinia gangrenosa and 1-methylisatin 3-thiosemicarbazone (methisazone)

1 January 2024

100

1 reference

https://api.crossref.org/works/10.1016/S0166-3542(03)00008-1

1 January 2024

Identifiers

1 reference

6 August 2017

1 reference